Unaudited Standalone Financial Result of the Company for the quarter ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 6.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Achyut Healthcare posted Q3 FY26 revenue from operations of Rs. 156.96 lakhs and net profit of just Rs. 0.43 lakhs, sharply down from the Rs. 254.65 lakhs revenue and Rs. 12.10 lakhs profit in the preceding Q2 FY26. For the nine months ended Dec 31, 2025, revenue surged to Rs. 720.83 lakhs from Rs. 212.66 lakhs a year earlier, but net profit fell to Rs. 23.73 lakhs from Rs. 38.59 lakhs, showing clear margin compression. The board also approved a preferential issue of up to 58 lakh equity shares at Rs. 6 each (Re. 1 face value, Rs. 5 premium) to raise about Rs. 3.48 crore, raised authorized capital from Rs. 24 crore to Rs. 26 crore, and shifted the registered office within Ahmedabad. The company recently migrated from the BSE SME platform to the BSE mainboard (effective Jan 2, 2026) and adopted Ind AS, with prior periods restated.
Mixed picture for shareholders: strong top-line growth in the nine-month period is offset by sharply weaker profitability and a quarter-on-quarter revenue dip. The preferential issue of 58 lakh new shares at Rs. 6 will dilute existing holders and signals the company is raising fresh equity rather than relying on internal accruals, though the small raise size limits the dilution impact.